Biocardia stock.

Richard has made over 43 trades of the BioCardia stock since 2007, according to the Form 4 filled with the SEC. Most recently he exercised 20,000 units of BCDA stock worth $14,600 on 17 June 2019.Pursuant to the Purchase Agreement, the Company agreed to sell to the Investors an aggregate 2,122,017 shares of the Company’s common stock at an offering price of $1.68 per share, the average ...Website. n/a. 33. Peter Altman. https://www.biocardia.com. BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of ...Oct 11, 2023 · Over the past 3 months, 4 analysts have published their opinion on BioCardia (NASDAQ:BCDA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a ...

2023 BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval. 16 Nov 2023 BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules.

BioCardia Inc. (NASDAQ:BCDA) trade information. BioCardia Inc. (BCDA) registered a 8.23% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 8.23% in intraday trading to $0.67 this Friday, 12/01/23, hitting a weekly high. The stock’s 5-day price performance is -5.22%, and it has moved by 77.43% in ...Get the latest BioCardia Inc (BCDA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

SUNNYVALE, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...The estimated Net Worth of Richard M Krasno is at least $411 Thousand dollars as of 17 June 2019. Mr. Krasno owns over 20,000 units of BioCardia stock worth over $140,700 and over the last 16 years he sold BCDA stock worth over $0. In addition, he makes $269,814 as Independent Director at BioCardia.16 Nov 2023 ... ... $BCDA STOCK ANALYSIS | BIOCARDIA STOCK Related topics : stock analysis stock chart stock news best stock best stocks bcda stock ...BioCardia has received a go-ahead from the FDA for a first-in-human trial of a second version of its stem cell implants designed to help rescue patients from heart failure. The green light clears ...

Sep 6, 2023 · SUNNYVALE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- BioCardia ®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...

Nov 17, 2023 · Source. Headline. Genocea Biosciences (NASDAQ:GNCAQ) vs. BioCardia (NASDAQ:BCDA) Financial Analysis. americanbankingnews.com - November 17 at 1:30 AM. BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. finance.yahoo.com - November 16 at 3:00 PM.

The estimated Net Worth of Peter Altman is at least $847 Thousand dollars as of 28 June 2019. Peter Altman owns over 600 units of BioCardia stock worth over $169,937 and over the last 5 years he sold BCDA stock worth over $0. In addition, he makes $677,501 as President, Chief Executive Officer, and Director at BioCardia.Nov 29, 2023 · BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules GlobeNewswire 18d Why Beyond Air Shares Are Trading Lower By Around 37%? Stock Performance. Shares of BioCardia were trading at $0.405 as of November 06. Over the last 52-week period, shares are down 78.11%. Given that these returns are generally negative, long-term ...BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmo...BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules (GlobeNewswire)-15.27%. Nov-15-23 11:04AM BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study (Zacks ... BioCardia, Inc. is a clinical-stage biotherapeutic company. It engages in the business of …mediaphotos. BioCardia (NASDAQ:BCDA) signed an agreement to provide its catheter biotherapeutic delivery product candidates for BlueRock Therapeutics' cell therapy products to treat heart failure ...155 articles about BioCardia, Inc. BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; ...

Discover historical prices for BCDA stock on Yahoo Finance. View daily, weekly or monthly format back to when BioCardia, Inc. stock was issued. Find the latest BioCardia, Inc. (BCDA) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.A high-level overview of BioCardia, Inc. (BCDA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.SAN CARLOS, Calif., July 01, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc., (OTC: BCDA), a leader in the development of comprehensive solutions for ...Jul 24, 2023 · July 24, 2023. SUNNYVALE, Calif. – BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announces that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the ongoing Phase III pivotal CardiAMP ...

Get the latest BioCardia, Inc. (BCDA) stock news and headlines to help you in your trading and investing decisions. ... 2023 BioCardia, Inc. reports earnings inline with expectations. Reported EPS ...

SUNNYVALE, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...Sep 5, 2023 · The treated group median 6MWT at 12M increased 36.1 with a standard deviation of ±70.8 meters, and the control group median 6MWT increased at 12M by 33.4 meters ± 74.8 meters (p =0.6). Results ... BioCardia announces $1.3M registered direct offering priced at-the-market. The Fly • 17 days ago. Track BioCardia Inc. (BCDA) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors. Nov 8, 2023 · BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 0% and 614%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock? The estimated Net Worth of Peter Altman is at least $849 Thousand dollars as of 28 June 2019. Peter Altman owns over 600 units of BioCardia stock worth over $171,654 and over the last 5 years he sold BCDA stock worth over $0. In addition, he makes $677,501 as President, Chief Executive Officer, and Director at BioCardia.BioCardia stock rises on FDA nod to start trial of stem cell therapy for heart failure Dec. 06, 2022 8:33 AM ET BioCardia, Inc. (BCDA) By: Ravikash , SA News Editor 1 Comment Sarah Silbiger2023 BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for …Related: H.C. Wainwright Sees Over 400% Upside For BioCardia Stock. The therapy incorporates a pre-procedural screening assay to identify patients who may be likely responders, ...

BioCardia, Inc. Warrant (BCDAW) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has entered into a definitive ...

Nov 8, 2023 · BioCardia Reports First Quarter 2023 Business Highlights and Financial Results. BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications. BioCardia to Host Q1 2023 Financial Results and Corporate Update Conference Call on May 10, 2023. SUNNYVALE, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided an update after its recent consultation with Japan’s Pharmaceutical and Medical Device Agency (PMDA) towards …5 Sep 2023 ... Biocardia stock dropped from about $2 on July 21 to $1.10 on July 24, when the concerns of the DSMB were first revealed. After drifting down ...Nov 15, 2023 · BioCardia, Inc. price | BioCardia, Inc. Quote Zacks Rank & Other Stocks to Consider. BioCardia currently carries a Zacks Rank #2 (Buy).Some other top-ranked stocks in the overall healthcare sector ... The FDA approved BioCardia Inc's NASDAQ:BCDA Phase 3 CardiAMP Heart Failure II study protocol of CardiAMP autologous cell therapy for ischemic heart failure.The currently ongoing CardiAMP Heart Failure trial has completed enrollment, and the final data analyses are anticipated to be reported in Q4…The main U.S. stock indexes were poised for strong opening gains on Tuesday after cooler-than-expected inflation data boosted expectations that the Federal Reserve was done raising interest rates.At 9:12 ET, Dow e-minis (1YMc1) were up 1.03% at 34,738. ... ** BioCardia BCDA: up 263.4% premarket. BUZZ - Rises on FDA's nod to …BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmo...Convert BioCardia Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. Select a stock. apple; wise; Select a currency. USD. NASDAQ: BioCardia Inc (BCDAW) = 0.06 USD. Provided by Alpha Vantage. BioCardia Inc stock (BCDAW) in USD. 1 BCDAW = 0.06 USD. 1 month.SUNNYVALE, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...Convert Biocardia Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. Select a stock. apple; wise; Select a currency. USD. NASDAQ: Biocardia Inc (BCDA) = 0.68 USD. Provided by Alpha Vantage. Biocardia Inc stock (BCDA) in USD.Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.SUNNYVALE, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided an update after its recent consultation with Japan’s Pharmaceutical and Medical Device Agency (PMDA) towards …

The estimated Net Worth of David Mc Clung is at least $440 Thousand dollars as of 5 November 2018. Mr. Clung owns over 1,600 units of BioCardia stock worth over $5,952 and over the last 6 years he sold BCDA stock worth over $0. In addition, he makes $434,495 as Chief Financial Officer at BioCardia.15 Nov 2023 ... BioCardia Inc (BCDA) is lower by Wednesday morning, with the stock declining -4.67% in pre-market trading to 1.02.Discover historical prices for BCDA stock on Yahoo Finance. View daily, weekly or monthly format back to when BioCardia, Inc. stock was issued.2023 BioCardia to Host Q2 2023 Financial Results and Corporate Update Conference Call on August 9, 2023 24 Jul 2023 BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is CollectedInstagram:https://instagram. fdig stockharry potter on iphonebest stocks to buy under dollar20state farm insurance jewelry The BioCardia stock prediction for 2025 is currently $ 139.62, assuming that BioCardia shares will continue growing at the average yearly rate as they did in the last 10 years. This would represent a 20,667.78% increase in the BCDA stock price. best stock options trading platformstocks below 10 dollars The estimated Net Worth of Peter Altman is at least $875 mil dollars as of 28 June 2019. Peter Altman owns over 600 units of BioCardia stock worth over $197,402 and over the last 5 years he sold BCDA stock worth over $0. In addition, he makes $677,501 as President, Chief Executive Officer y Director at BioCardia. which is the best broker for option selling BioCardia Inc. (NASDAQ:BCDA) trade information. BioCardia Inc. (BCDA) registered a 8.23% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 8.23% in intraday trading to $0.67 this Friday, 12/01/23, hitting a weekly high. The stock’s 5-day price performance is -5.22%, and it has moved by …BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq ...